When biotechnology company Biogen announced the cancellation of the trial for their Alzheimer’s drug aducanumab, nearly 3,500 trial participants were left in limbo. Now,…
SAN DIEGO — The scientific data was virtually unreadable, the explanations often too complex for the layman or woman to understand. But there was…
Was it too good to be true? China last week awarded conditional approval for a new seaweed-based drug for Alzheimer’s, but experts in the…
Scientists and analysts greeted yesterday’s announcement that Biogen is trying to resurrect aducanumab, its experimental Alzheimer’s drug, with caution and outright skepticism. Minutes after…
